Winning moment: Russian COVID-19 vaccine Sputnik V found 91.6% efficient in Phase III trial Associated Press
New Delhi: The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) said Tuesday that interim results of the Phase III clinical trials of COVID-19 vaccine ‘Sputnik V’ showed 91.6 per cent efficacy against the pandemic. Medical journal ‘The Lancet’ has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine’s high efficacy and safety, they said in a joint statement.
“In the interim efficacy analysis of the randomised, double-blind, placebo-controlled clinical trial, where data on 19,866 volunteers were included in the efficacy analysis (14,964 of whom received the vaccine and 4,902 the placebo) the two-dose treatment of Sputnik V administered 21 days apart demonstrated efficacy of 91.6 per cent against COVID-19,” the statement said.
A vaccine for all mankind: Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
In an interim analysis of a Phase III clinical trial, Sputnik V
showed
Efficacy of Sputnik V against COVID-19 was reported at 91.6%.
- Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
- Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group.
Sputnik V provides full protection against severe cases of COVID-19.
The News Scroll 02 February 2021
Last Updated at 7:31 pm | Source: PTI
Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF Outlook February 02, 2021 19:31 IST Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF outlookindia.com 1970-01-01T05:30:00+0530
New Delhi, Feb 2 (PTI) The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) on Tuesday said that interim results of a Phase III clinical trial of COVID-19 vaccine Sputnik V showed 91.6 per cent efficacy against the pandemic. Medical journal The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine s high efficacy and safety, they said in a joint statement.
India key production partner for Russia s Sputnik V vaccine, says RDIF CEO ANI | Updated: Feb 02, 2021 23:43 IST
Moscow [Russia], February 2 (ANI): India is the key production partner for Russia s Sputnik V vaccine against the coronavirus, Kirill Dmitriev, Chief Executive Officer (CEO) of Russian Direct Investment Fund (RDIF) said on Tuesday. India is a key partner in terms of production of vaccine and we do expect that there will be restricted emergency use order for Sputnik V vaccine this month or next. After that, we will be able to start our vaccine delivery to India Dmitriev told ANI. The data published by The Lancet shows that Sputnik V is one of only three vaccines in the world with the efficacy of over 90 per cent but outperforms them in terms of safety, ease of transportation due to storage requirements of +2 to +8 degrees, and a more affordable price. Sputnik V is a vaccine for all mankind, Dmitriev said.
India is key production partner for Russia s Sputnik V sierraleonetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sierraleonetimes.com Daily Mail and Mail on Sunday newspapers.